RecruitingNCT05776147

Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study


Sponsor

Latin American Cooperative Oncology Group

Enrollment

400 participants

Start Date

Nov 9, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria5

  • Women over 18 years old;
  • Diagnosis of breast cancer of any molecular subtype;
  • Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively;
  • Treated from December/2019 onward;
  • With clinical and treatment data available in medical records.

Locations(11)

ICC - Instituto do Câncer do Ceará

Fortaleza, Ceará, Brazil

Hospital Sírio-Libanês DF

Brasília, Federal District, Brazil

Hospital Márcio Cunha da Fundação São Francisco Xavier (HMC-FSFX)

Ipatinga, Minas Gerais, Brazil

Oncominas - Clínica de Oncologia no Sul de Minas

Pouso Alegre, Minas Gerais, Brazil

Real Hospital Português de Beneficência em Pernambuco

Recife, Pernambuco, Brazil

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP

Ribeirão Preto, São Paulo, Brazil

Instituto COI - Clínicas Oncológicas Integradas (Instituto Américas RJ)

Rio de Janeiro, Brazil

Hospital Sírio-Libanês SP

São Paulo, Brazil

HAOC - Hospital Alemão Oswaldo Cruz

São Paulo, Brazil

BP - A Beneficência Portuguesa de São Paulo

São Paulo, Brazil

A.C. Camargo Cancer Center

São Paulo, Brazil

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05776147


Related Trials